Loading...
Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The leading treatment for high-risk MDS patients is azacitidine (Aza, Vidaza(®)), but a significant proportion of patients are refractory and all patients e...
Na minha lista:
| Udgivet i: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6981810/ https://ncbi.nlm.nih.gov/pubmed/31881723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21010164 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|